Prenetics Global Limited (NASDAQ:PRE) Short Interest Update

Prenetics Global Limited (NASDAQ:PRE) was the recipient of a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 38,700 shares, a growth of 19.8% from the October 15th total of 32,300 shares. Currently, 0.5% of the shares of the company are sold short. Based on an average daily trading volume, of 19,300 shares, the days-to-cover ratio is currently 2.0 days.

Prenetics Global Price Performance

PRE stock traded down $0.31 on Friday, reaching $4.50. 3,880 shares of the company were exchanged, compared to its average volume of 5,355. The firm has a market capitalization of $41.13 million, a PE ratio of -1.39 and a beta of -0.20. Prenetics Global has a 12 month low of $2.85 and a 12 month high of $7.84. The stock’s fifty day moving average price is $4.53 and its 200 day moving average price is $5.27.

Prenetics Global (NASDAQ:PRE) last posted its quarterly earnings data on Monday, October 7th. The company reported ($0.88) earnings per share (EPS) for the quarter. Prenetics Global had a negative return on equity of 15.70% and a negative net margin of 229.17%. The company had revenue of $5.94 million for the quarter. As a group, research analysts expect that Prenetics Global will post -3.32 EPS for the current fiscal year.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.